Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada
From: Multiple Sclerosis News Today By: Marisa Wexler MS Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS treatments in Canada by […]
Implications of Expanded Biosimilar Use in the United States’ Dermatology, Gastroenterology, Rheumatology, Ophthalmology, Nephrology, and Neurology Markets Highlighted in New Spherix Study
450 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment landscape EXTON, Pa., December 8, 2021 /PRNewswire/ – Biosimilars are biopharmaceutical products that are nearly identical copies of drugs that have previously been licensed (reference products), with no clinically meaningful efficacy and safety differences from […]
EMD Serono’s Mavenclad and Novartis’ Kesimpta Emerging as Growth Brands After Eventful 2021 for the Multiple Sclerosis Market in Canada
Content Area
Physician Hesitation to Prescribe Biogen/Eisai’s Aduhelm in Alzheimer’s Disease Grows Amid Controversies
As brand satisfaction and patient candidacy numbers continue to erode, Spherix will assess the impact of the recent patient death potentially linked to Aduhelm EXTON, Pa., December 1, 2021 /PRNewswire/ — For those of us following the evolution of neurology pharmaceutical markets, 2021 will be remembered by many for the tumultuous roll out of Biogen/Eisai’s Aduhelm (aducanumab) […]
J&J’s Neuroscience Renaissance? Janssen R&D Chief Readying For ‘Golden Age’
Content Area
The Very Slow Roll of Biogen’s Aduhelm: Neurologists Weigh in on Patients, Practices and Payments Amid Ongoing Media Storm
From: Endpoints News By: Beth Snyder Bulik Five months after the approval of Biogen’s Aduhelm, the bad news just keeps piling up for the Alzheimer’s drug. The confirmation yesterday of a Biogen investigation into the death of trial participant is the latest setback, but it adds to a laundry list of ongoing woes including […]
Ocrevus Still Top Therapy for Progressive MS Forms, Report Finds
From: Multiple Sclerosis News Today By: Marisa Wexler MS Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for progressive forms of multiple sclerosis (MS), including primary progressive MS (PPMS) and secondary progressive MS (SPMS), according to an analysis from the market intelligence firm Spherix Global Insights. However, other therapies are “gaining traction” among SPMS patients, the report finds…(read more)
Genentech’s Trailblazing Ocrevus Maintains Leading Position in the Progressive Multiple Sclerosis Space, But Emerging Bruton’s Tyrosine Kinase Inhibitors Could Threaten Its Long-Term Dominance
New patient-level data show that newer market entrants, such as BMS’ Zeposia and Novartis’ Kesimpta, are gaining traction in the US treatment algorithm EXTON, Pa., November 4, 2021/PRNewswire/ – Although the population of multiple sclerosis (MS) patients with progressive disease remains underserved, several recent approvals for relapsing MS (RMS), which includes active secondary progressive […]
Migraine Marketing Wars? AbbVie, Biohaven, Eli Lilly, Amgen Lead Push for Attention in Newly Competitive Space
From: Endpoints News By: Beth Snyder Bulik For a long time, migraine sufferers were stuck with the same old medicines and advice. Try some triptans, change your diet, maybe even see if a narcotic might help — but no major drug advances to prevent or stop debilitating migraine episodes in almost 30 years…(read more)
Buckle Up AbbVie, Amgen: Biohaven’s Oral CGRP Drug is Gaining Traction in Migraine, Doctors’ Survey Shows
From: FiercePharma By: Angus Liu With recent FDA approvals, the race for supremacy in migraine treatment is heating up among oral CGRP inhibitors, and a doctors’ survey is offering an early look at the winners. Piper Sandler conducted the survey with Spherix Global Insights a few weeks ahead of Qulipta’s FDA go-ahead in late […]
